Model Answer

Biological therapies (biologics) represent a major advancement in modern medicine, especially in the treatment of cancer, autoimmune disorders, asthma and rheumatoid arthritis. Unlike conventional chemical drugs, biologics are derived from living systems and target specific disease pathways, leading to higher efficacy and lower toxicity. However, their high cost severely restricts access in India. In this context, biosimilars and the government’s Biopharma Shakti initiative assume critical importance in improving affordability, access, and self-reliance in healthcare.

What are Biosimilars?

• Biosimilars are biological medicines that are highly similar to an already approved reference biologic drug, with no clinically meaningful differences in terms of safety, efficacy, and quality.
• They are not exact copies (unlike generic chemical drugs) because biologics are complex molecules produced using living cells.
• Rigorous comparability studies, clinical trials, and regulatory scrutiny are required to establish similarity.
• When properly developed and regulated, biosimilars can deliver equivalent clinical outcomes at significantly lower costs.

Thus, biosimilars offer a pragmatic pathway to expand access to advanced therapies in resource-constrained settings like India.

Need for Biosimilars in India

Despite being the “pharmacy of the world” for generic drugs, India faces several challenges in biologics:

• Affordability Gap Original biologics are often priced beyond the reach of most Indian patients. High out-of-pocket healthcare expenditure exacerbates inequity in access.

• Rising Disease Burden Increase in cancer, lifestyle diseases, and autoimmune disorders has raised demand for biologic therapies.

• Import Dependence India remains dependent on multinational companies for many high-end biologics, posing strategic and economic risks.

Biosimilars, therefore, are crucial to bridge the gap between medical advancement and public health access.

Biopharma Shakti Initiative: Overview

Biopharma Shakti is a government-led mission to transform India into a global biopharmaceutical manufacturing and innovation hub. It aims to address structural bottlenecks that have slowed India’s progress in biologics and biosimilars.

The initiative focuses on:

• Strengthening research and development
• Expanding clinical trial capacity
• Enhancing regulatory expertise
• Building world-class manufacturing and quality systems
• Developing a skilled biopharma workforce

How Biopharma Shakti Improves Access to Biological Therapies

1. Boosting Domestic Biosimilar Production

• Encourages indigenous development and manufacturing of biosimilars.
• Reduces dependence on costly imports.
• Economies of scale and competition can significantly lower prices, improving affordability.

2. Strengthening Regulatory and Quality Ecosystems

• Biologics require stringent quality control, precision manufacturing, and regulatory oversight.
• Biopharma Shakti seeks to upgrade regulatory capacity and harmonize standards with global benchmarks.
• This builds trust in Indian biosimilars both domestically and internationally.

3. Enhancing Research, Clinical Trials and Innovation

• Supports translational research and clinical trial infrastructure.
• Facilitates collaboration between academia, startups, industry, and public institutions.
• Enables not only biosimilars but also original biologic innovation in the long run.

4. Skill Development and Human Capital Creation

• Biologics manufacturing demands advanced skills in cell biology, bioprocessing, and quality assurance.
• Focused investment in training scientists, regulators, and technicians improves production reliability and safety.

5. Mission-Mode Execution and Collaboration

• Inspired by ISRO-like mission orientation, Biopharma Shakti emphasizes:
• Clear targets
• Time-bound execution
• Public–private partnerships

Such coordination is essential for a capital- and knowledge-intensive sector like biopharma.

Biosimilars represent a critical tool for democratizing access to life-saving biological therapies in India. The Biopharma Shakti initiative, through mission-mode execution, skill development, regulatory strengthening, and innovation support, has the potential to transform India into a biopharmaceutical powerhouse. If implemented effectively, it can simultaneously ensure affordable healthcare for citizens and strategic self-reliance with global competitiveness, aligning public health goals with economic and technological advancement.